Lower sales costs boost ATL profits
Officials of ultrasound vendor Advanced Technology Laboratoriescredit product cost reductions and the end of restructuring costsrelated to its acquisition of Interspec for a profitable firstquarter (end-March). Net income for the quarter rose to $3
Officials of ultrasound vendor Advanced Technology Laboratoriescredit product cost reductions and the end of restructuring costsrelated to its acquisition of Interspec for a profitable firstquarter (end-March).
Net income for the quarter rose to $3 million compared witha $274,000 loss in the same period of 1995. Sales of $94.8 millionwere up slightly compared with $94.4 million in last year's firstquarter, but the company reduced product sales costs and no longerfaced the restructuring charges that took the blame for most ofits first-quarter 1995 losses.
Chairman and chief executive Dennis Fill expects further improvementin the company's results due to its new sales effort in Japanand from a recent Food and Drug Administration ruling that willallow ATL to market the use of its Ultramark 9 HDI scanner forspecialized breast imaging applications.
Hitachi, ATL's distribution partner in Japan, is moving forwardwith its marketing campaign after gaining all necessary Japanesegovernment approvals in that country for the HDI 3000 premiumscanner, according to Fill. On April 12, ATL announced that theFDA had approved its premarket approval application to use Ultramark9 HDI as an adjunct to mammography to differentiate suspiciousmasses (SCAN 4/24/96).
Officials at the Bothell, WA, company also expect to beginshipments this month of HDI 3000 scanners equipped with the vendor'snew 3-D vascular visualization features.
What a New Mammography Study Reveals About BMI, Race, Ethnicity and Advanced Breast Cancer Risk
December 8th 2023In a new study examining population attributable risk proportions (PARPs) based on data from over three million screening mammography exams, researchers found that postmenopausal Black women had the highest BMI-related PARP and premenopausal Asian and Pacific Islander women had the highest breast density-related PARP for advanced breast cancer.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
